Trial Profile
B-FOLFIRI followed by B-FOLFOX/B-XELOX or the reverse sequence versus standard B-FOLFIRI for the first-line treatment of metastatic colorectal cancer: a randomized SICOG study. SEveSTA study (Sequential vs Standard) SICOG 13/02
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Feb 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 26 Feb 2018 New trial record